DUBLIN–(BUSINESS WIRE)–The “Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis” report has been added to ResearchAndMarkets.com’s offering.
The hematuria treatment market is projected to reach US$ 1,103.61 million by 2028 from US$ 932.89 million in 2021; it is estimated to grow at a CAGR of 2.4% from 2021 to 2028.
Factors such as the high prevalence of hematuria-associated indications, and increasing awareness about treatment options and improving healthcare expenditure are driving the market growth. However, the undiagnosed cases of associated indications affect the effectiveness of hematuria treatments, thereby hampering the market growth. The hematuria treatment market in APAC is growing a significant pace. The restrictions imposed by governments to contain the COVID-19 spread have impacted ongoing clinical research. However, with gradual relaxations in these restrictions, the research activities are gaining momentum, which is likely to boost the demand for hematuria treatment in the coming years.
Based on treatment, the hematuria treatment market is segmented into drugs, therapies, and others. The drugs and therapies segment is expected to account for the largest market share in 2020. It is further expected to register the highest CAGR in the market during 2020-2028. Based on indication, the hematuria treatment market is segmented into urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation.
The urinary tract infections segment led the market in 2020 with a share of 17.31%, and it is expected to retain its dominance during the forecast period. Based on type, the hematuria treatment market is segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. The microscopic hematuria segment would hold the largest market share in 2021. The market for macroscopic hematuria segment is expected to grow at a CAGR of 2.6% during the forecast period. Based on end use, the hematuria treatment market is further segmented into hospitals, clinics, ASCs, and others. The hospital segment led the market in 2020 with a share of 36.52%, and it is expected to retain its dominance during the forecast period.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the hematuria treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global hematuria treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Market Dynamics
Drivers
- High Prevalence of Hematuria-Associated Indications
- Increasing Awareness About Treatment Options and Improving Healthcare Expenditure
Restraints
- Undiagnosed Cases of Associated Indications
Opportunities
- Increasing Opportunities for Related Treatments
Future Trends
- Rise in Preference for Advanced Therapies
Companies Mentioned
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
For more information about this report visit https://www.researchandmarkets.com/r/oc7x5q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900